PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-06-16
DOI
10.1186/s12933-022-01542-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
- (2022) Lorenz Räber et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
- (2022) Stephen J. Nicholls et al. JACC-Cardiovascular Imaging
- PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations
- (2022) Qiukui Hao et al. BMJ-British Medical Journal
- Insight into the Evolving Role of PCSK9
- (2022) Mateusz Maligłówka et al. Metabolites
- PCSK9: a view beyond the canonical cholesterol lowering impact
- (2021) Chiara Macchi et al. AMERICAN JOURNAL OF PATHOLOGY
- Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON
- (2021) Alberto J. Lorenzatti et al. Cardiovascular Diabetology
- Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
- (2021) Laurenz T. Fischer et al. Cardiovascular Diabetology
- Inclisiran
- (2021) Bruce A. Warden et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe/placebo in patients at high cardiovascular risk
- (2021) Wenfang Ma et al. ATHEROSCLEROSIS
- Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors
- (2021) Borja E. Sanz-Cuesta et al. STROKE
- Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
- (2021) Qiang Geng et al. Cardiology Journal
- Meta‐analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD
- (2021) Azita H. Talasaz et al. PHARMACOTHERAPY
- Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials
- (2020) Guangyan Mu et al. ADVANCES IN THERAPY
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis
- (2020) Paul Guedeney et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
- (2020) Ning Kam et al. PHARMACOECONOMICS
- Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia
- (2019) Wieneke Dijk et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
- (2019) Paul Guedeney et al. EUROPEAN HEART JOURNAL
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Role of PCSK9 in lipid metabolism and atherosclerosis
- (2018) Xiao-Long Lin et al. BIOMEDICINE & PHARMACOTHERAPY
- Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
- (2018) Emelia J. Benjamin et al. CIRCULATION
- A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes
- (2018) Safi U Khan et al. European Journal of Preventive Cardiology
- Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Peter W.F. Wilson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bococizumab for the treatment of hypercholesterolaemia
- (2017) Nicola Ferri et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
- (2017) Peter P. Toth et al. Journal of the American Heart Association
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
- (2015) Nathalie Bergeron et al. CIRCULATION
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy
- (2012) Samia Mora et al. CIRCULATION
- Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor–independent pathways
- (2012) Jamie Cameron et al. Translational Research
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started